Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC)

• Published in: Journal of clinical oncology Vol. 40; no. 16_suppl; p. 8517
• Main Authors: Goldman, Jonathan W., Cummings, Amy Lauren, Mendenhall, Melody A., Velez, Maria A, Babu, Sunil, Johnson, Tirrell T., Alcantar, Juan M., Dakhil, Shaker R., Kanamori, David E., Lawler, William E., Anand, Sidharth, Chauv, James, Garon, Edward B., Slamon, Dennis J.
• Format: Journal Article
• Language: English
• Published: American Society of Clinical Oncology 01.06.2022

8517Background: TALA exhibits cytotoxic effects by inhibiting poly (ADP-ribose) polymerase (PARP) proteins 1 and 2 in addition to "trapping" PARP on DNA. TMZ has been shown to increase antitumor response when combined with TALA in SCLC models (Wainberg AACR 2016). TALA plus TMZ as second-l...